Pharmacological action
Recombinant human interferon obtained by genetic engineering using a culture of Chinese hamster ovary cells. The amino acid sequence in the interferon beta-1a molecule is identical to that of endogenous human interferon beta.
Has immunomodulatory, antiviral and antiproliferative properties.
The mechanism of action in patients with multiple sclerosis has not been fully studied; This interferon has been shown to help limit the damage to the central nervous system that underlies the disease.
Indications of the active substances of the drug Avonex
Outpatient treatment of patients with multiple sclerosis (to reduce the frequency and severity of exacerbations and slow the progression of disability).
Contraindications for use
Severe depression and/or suicidal ideation; epilepsy in the absence of effect from the use of appropriate therapy; pregnancy; lactation; children and adolescents up to 16 years of age; hypersensitivity to endogenous or recombinant interferon beta, human serum albumin.
Dosage and administration
Add s.c. Recommended dose – 22-44 mcg 3 times/week. at the same time (preferably in the evening), on certain days of the week, with an interval of at least 48 hours.
When first used, it is recommended to administer a single dose of 8.8 mcg during the first 2 weeks, during the 3rd and 4th weeks – 22 mcg starting from the 5th week onwards – 44 mcg.
